Patient-specific modifiers of survival benefit in cardiac resynchronization therapy - A multicentre interaction analysis.

In the COMPANION trial, a CRT‐D was associated with a significant 36% decrease in the risk of all‐cause mortality, while for CRT‐P, the observed 24% decrease did not reach statistical significance ( P = 0.059). 3 The choice between CRT‐D and CRT‐P depends on the interplay of individual patient characteristics, underlying cardiac pathology, comorbidities, risk of ventricular arrhythmias and patient preferences.

also in 111,027 other papers